NCT03470311

Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 20 (actual)
• Sponsor: McMaster University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In severe prednisone-dependent eosinophilic asthma, Benralizumab would suppress airway eosinophilia that is not suppressed by either Mepolizumab or Reslizumab and this would be associated with greater asthma control

Detailed description

Benralizumab thus targets 'eosinophil biology', by inhibiting the interleukin (IL-5) receptor signalling, and inducing apoptosis in cells with an IL-5receptor. Hence, for patients who remain 'uncontrolled' on anti-IL-5 therapy (with detectable eosinophil activity and IL5-Rα+ cells in the airways), the investigators believe would benefit from a strategy that not only reduces eosinophil proliferation/recruitment/maturation, but also depletes cells capable of inducing downstream IL-5 signalling.

Conditions

• Severe Prednisone Dependent Eosinophilic Asthma

Interventions

Type	Name	Description
BIOLOGICAL	Benralizumab	30mg in 1mL pre-filled syringe
BIOLOGICAL	Placebo	Matched placebo (1mL) in pre-filled syringe

Timeline

• Start date: 2018-04-26
• Primary completion: 2022-06-14
• Completion: 2022-11-30
• First posted: 2018-03-19
• Last updated: 2023-01-20

Locations

1 site across 1 country: Canada